Fibroblast growth factor-23 is regulated by 1α,25-dihydroxyvitamin D

Journal of Bone and Mineral Research

Volumn 20, Issue 11, 2005, Pages 1944-1950

  Collins, Michael T ^a   Lindsay, John R ^b   Jain, Alka ^c   Kelly, Marilyn H ^b   Cutler, Carolee M ^a   Weinstein, Lee S ^d   Liu, Jie ^d   Fedarko, Neal S ^c,e   Winer, Karen K ^f  

^a NATIONAL INSTITUTE OF DENTAL AND CRANIOFACIAL RESEARCH   (United States)

^b NATIONAL INSTITUTES OF HEALTH   (United States)

^c JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES   (United States)

^e JOHNS HOPKINS BAYVIEW MEDICAL CENTER   (United States)

^f EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH AND HUMAN DEVELOPMENT   (United States)

Author keywords

1 hydroxylase; Fibroblast growth factor 23; Fibrous dysplasia; Hypoparathyroidism; McCune Albright syndrome; Phosphate; Phosphaturia; Phosphorus; Pseudohypoparathyroidism; Vitamin D

Indexed keywords

1,25 DIHYDROXYERGOCALCIFEROL; ALKALINE PHOSPHATASE; CALCITRIOL; CALCIUM; FIBROBLAST GROWTH FACTOR 23; PARATHYROID HORMONE[1-34];

ADULT; ARTICLE; BONE DYSPLASIA; CASE REPORT; DRUG MEGADOSE; FEMALE; HORMONAL REGULATION; HUMAN; HUNGRY BONE SYNDROME; HYPERPARATHYROIDISM; HYPOCALCEMIA; HYPOPARATHYROIDISM; MINERAL METABOLISM; MUNCHAUSEN SYNDROME; PARATHYROIDECTOMY; PHOSPHATE METABOLISM; PHOSPHATURIA; PROTEIN ANALYSIS; PROTEIN BLOOD LEVEL; PSEUDOHYPOPARATHYROIDISM; PSEUDOHYPOPARATHYROIDISM 1B; SYNDROME; VITAMIN D METABOLISM;

ADULT; CALCITRIOL; CALCIUM; FEMALE; FIBROBLAST GROWTH FACTORS; FIBROUS DYSPLASIA, POLYOSTOTIC; HUMANS; HYPOPARATHYROIDISM; MIDDLE AGED; PHOSPHORUS; PSEUDOHYPOPARATHYROIDISM; TERIPARATIDE;

EID: 27444437568     PISSN: 08840431     EISSN: None     Source Type: Journal    
DOI: 10.1359/JBMR.050718     Document Type: Article

References (38)

1. Cai Q, Hodgson SF, Kao PC, Lennon VA, Klee GG, Zinsmiester AR, Kumar R 1994 Brief report: Inhibition of renal phosphate transport by a tumor product in a patient with oncogenic osteomalacia. N Engl J Med 330:1645-1649.
2. McCrance RA 1947 Osteomalacia and Looser's nodes (milk-man's syndrome) due to a raised resistance to vitamin D acquired about the age of 15 years. Q J Med 16:33-46.
3. De Beur SM, Finnegan RB, Vassiliadis J, Cook B, Barberio D, Estes S, Manavalan P, Petroziello J, Madden SL, Cho JY, Kumar R, Levine MA, Schiavi SC 2002 Tumors associated with oncogenic osteomalacia express genes important in bone and mineral metabolism. J Bone Miner Res 17:1102-1110.
4. Carpenter TO, Ellis BK, Insogna KL, Philbrick WM, Sterpka J, Shimkets R 2004 FGF7-an inhibitor of phosphate transport derived from oncogenic osteomalacia-causing tumors. J Clin Endocrinol Metab 90:1012-1020.
5. Blumsohn A 2004 What have we learnt about the regulation of phosphate metabolism? Curr Opin Nephrol Hypertens 13:397-401.
6. ADHR Consortium 2000 Autosomal dominant hypophosphataemic rickets is associated with mutations in FGF23. The ADHR Consortium. Nat Genet 26:345-348.
7. White KE, Jonsson KB, Carn G, Hampson G, Spector TD, Mannstadt M, Lorenz-Depiereux B, Miyauchi A, Yang IM, Ljunggren O, Meitinger T, Strom TM, Juppner H, Econs MJ 2001 The autosomal dominant hypophosphatemic rickets (ADHR) gene is a secreted polypeptide overexpressed by tumors that cause phosphate wasting. J Clin Endocrinol Metab 86:497-500.
8. Yamazaki Y, Okazaki R, Shibata M, Hasegawa Y, Satoh K, Tajima T, Takeuchi Y, Fujita T, Nakahara K, Yamashita T, Fukumoto S 2002 Increased circulatory level of biologically active full-length FGF-23 in patients with hypophosphatemic rickets/osteomalacia. J Clin Endocrinol Metab 87:4957-4960.
9. Riminucci M, Collins MT, Fedarko NS, Cherman N, Corsi A, White KE, Waguespack S, Gupta A, Hannon T, Econs MJ, Bianco P, Gehron Robey P 2003 FGF-23 in fibrous dysplasia of bone and its relationship to renal phosphate wasting. J Clin Invest 112:683-692.
10. Benet-Pages A, Orlik P, Strom TM, Lorenz-Depiereux B 2004 An FGF23 missense mutation causes familial tumoral calcinosis with hyperphosphatemia. Hum Mol Genet 114:385-390.
11. Larsson T, Yu X, Davis SI, Draman MS, Mooney SD, Cullen MJ, White KE 2005 A novel recessive mutation in Fibroblast growth factor-23 (FGF23) causes familial tumoral calcinosis. J Clin Endocrinol Metab 90:2424-2427.
12. Shimada T, Mizutani S, Muto T, Yoneya T, Hino R, Takeda S, Takeuchi Y, Fujita T, Fukumoto S, Yamashita T 2001 Cloning and characterization of FGF23 as a causative factor of tumor-induced osteomalacia. Proc Natl Acad Sci USA 98:6500-6505.
13. Shimada T, Kakitani M, Yamazaki Y, Hasegawa H, Takeuchi Y, Fujita T, Fukumoto S, Tomizuka K, Yamashita T 2004 Targeted ablation of Ffg23 demonstrates an essential physiological role of FGF23 in pohsphate and vitamin D metabolism. J Clin Invest 113:561-568.
14. Larsson T, Marsell R, Schipani E, Ohlsson C, Ljunggren O, Tenenhouse HS, Juppner H, Jonsson KB 2004 Transgenic mice expressing fibroblast growth factor 23 under the control of the {alpha}1(I) collagen promoter exhibit growth retardation, osteomalacia and disturbed phosphate homeostasis. Endocrinology 145:3087-3094.
15. Bai X, Miao D, Li J, Goltzman D, Karaplis AC 2004 Transgenic mice overexpressing human fibroblast growth factor 23 (R176Q) delineate a putative role for parathyroid hormone in renal phosphate wasting disorders. Endocrinology 145:5269-5279.
16. Mirams M, Robinson BG, Mason RS, Nelson AE 2004 Bone as a source of FGF23: Regulation by phosphate? Bone 35:1192-1199.
17. Sitara D, Razzaque MS, Hesse M, Yoganathan S, Taguchi T, Erben RG, Lanske B 2004 Homozygous ablation of fibroblast growth factor-23 results in hyperphosphatemia and impaired skeletogenesis, and reverses hypophosphatemia in Phex-deficient mice. Matrix Biol 23:421-432.
18. Shimada T, Hasegawa H, Yamazaki Y, Muto T, Hino R, Takeuchi Y, Fujita T, Nakahara K, Fukumoto S, Yamashita T 2004 FGF-23 is a potent regulator of vitamin D metabolism and phosphate homeostasis. J Bone Miner Res 19:429-435.
19. Saito H, Maeda A, Ohtomo SI, Hirata M, Kusano K, Kato S, Ogata E, Segawa H, Miyamoto KI, Fukushima N 2004 Circulating FGF-23 is regulated by la,25-dihydroxyvitamin D3 and phosphorus in vivo. J Biol Chem 280:2543-2549.
20. Gupta A, Winer K, Econs MJ, Marx SJ, Coffins MT 2004 FGF-23 is elevated by chronic hyperphosphatemia. J Clin Endocrinol Metab 89:4489-4492.
21. Ferrari SL, Bonjour JP, Rizzoli R 2005 Fibroblast growth factor-23 relationship to dietary phosphate and renal phosphate handling in healthy young men. J Clin Endocrinol Metab 90:1519-1524.
22. Shenker A, Chanson P, Weinstein LS, Chi P, Spiegel AM, Lomri A, Marie PJ 1995 Osteoblastic cells derived from isolated lesions of fibrous dysplasia contain activating somatic mutations of the Gs alpha gene. Hum Mol Genet 4:1675-1676.
23. McCune DJ 1936 Osteitis fibrosa cystica: The case of a nine-year-old girl who also exhibits precocious puberty, multiple pigmentation of the skin and hyperthyroidism. Am J Dis Child 52:743-744.
24. Liu J, Nealon JG, Weinstein LS 2005 Distinct patterns of abnormal GNAS imprinting in familial and sporadic pseudohypoparathyroidism type IB. Hum Mol Genet 14:95-102.
25. Bijvoet OL, Morgan DB, Fourman P 1969 The assessment of phosphate reabsorption. Clin Chim Acta 26:15-24.
26. DiMeglio LA, White KE, Econs MJ 2000 Disorders of phosphate metabolism. Endocrinol Metab Clin North Am 29:591-609.
27. Ito M, Sakai Y, Furumoto M, Segawa H, Haito S, Yamanaka S, Nakamura R, Kuwahata M, Miyamoto KI 2005 Vitamin D and phosphate regulate fibroblast growth factor-23 in K562 cells. Am J Physiol Endocrinol Metab 288:E1101-E1109.
28. Murer H, Biber J 1996 Control of proximal tubular apical Na/Pi cotransport. Exp Nephrol 4:201-204.
29. Bowe AE, Finnegan R, Jan de Beur SM, Cho J, Levine MA, Kumar R, Schiavi SC 2001 FGF-23 inhibits renal tubular phosphate transport and is a PHEX substrate. Biochem Biophys Res Commun 284:977-981.
30. Larsson T, Nisbeth U, Ljunggren O, Juppner H, Jonsson KB 2003 Circulating concentration of FGF-23 increases as renal function declines in patients with chronic kidney disease, but does not change in response to variation in phosphate intake in healthy volunteers. Kidney Int 64:2272-2279.
31. Weber TJ, Liu S, Indridason OS, Quarles LD 2003 Serum FGF23 levels in normal and disordered phosphorus homeostasis. J Bone Miner Res 18:1227-1234.
32. Shigematsu T, Kazama JJ, Yamashita T, Fukumoto S, Hosoya T, Gejyo F, Fukagawa M 2004 Possible involvement of circulating fibroblast growth factor 23 in the development of secondary hyperparathyroidism associated with renal insufficiency. Am J Kidney Dis 44:250-256.
33. Singh RJ, Kumar R 2003 Fibroblast growth factor 23 concentrations in humoral hypercalcemia of malignancy and hyperparathyroidism. Mayo Clin Proc 78:826-829.
34. Yamashita H, Yamashita T, Miyamoto M, Shigematsu T, Kazama JJ, Shimada T, Yamazaki Y, Fukumoto S, Fukagaw M, Noguchi S 2004 Fibroblast growth factor (FGF)-23 in patients with primary hyperparathyroidism. Eur J Endocrinol 151:55-60.
35. Tebben PJ, Singh RJ, Clarke BL, Kumar R 2004 Fibroblast growth factor 23, parathyroid hormone, and 1alpha,25-dihydroxyvitamin D in surgically treated primary hyperparathyroidism. Mayo Clin Proc 79:1508-1513.
36. Yamamoto T, Miyamoto KI, Ozono K, Taketani Y, Katai K, Miyauchi A, Shima M, Yoshikawa H, Yoh K, Takeda E, Okada S 2001 Hypophosphatemic rickets accompanying McCune-Albright syndrome: Evidence that a humoral factor causes hypophosphatemia. J Bone Miner Metab 19:287-295.
37. Bianco P, Kuznetsov SA, Riminucci M, Fisher LW, Spiegel AM, Robey PG 1998 Reproduction of human fibrous dysplasia of bone in immunocompromised mice by transplanted mosaics of normal and Gsalpha-mutated skeletal progenitor cells. J Clin Invest 101:1737-1744.
38. Corsi A, Collins MT, Riminucci M, Howell PG, Boyde A, Robey PG, Bianco P 2003 Osteomalacic and hyperparathyroid changes in fibrous dysplasia of bone: Core biopsy studies and clinical correlations. J Bone Miner Res 18:1235-1246.